AzTrials
AzTrials

AneurysmsSTERLINGNCT03642639

A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms

A study testing MICRUSFRAME and GALAXY coils in people with Aneurysms, run by Cerenovus, Part of DePuy Synthes Products, Inc. at 51 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils Read more about this study

Who is it for?
Ages 21 to 80 years
Conditions the study is for
Aneurysms
What is being tested?
MICRUSFRAME and GALAXY coils
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
723 participants
Where
51 sitesin 10 countries
Study dates
23 Aug 2018to 12 Jun 2025
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient is between 21 and 80 years of age
  • Patient has an intracranial saccular aneurysm, ruptured or unruptured, suitable for embolization with coils
  • Patient is able and willing to comply with protocol and follow-up requirements

Who cannot join

  • Pre-planned staged procedure on unruptured aneurysm
  • More than one aneurysm requiring treatment during the course of study
  • Fusiform aneurysm

Trial locations and contacts

51 sites in 10 countries.

51 sites in 10 countries

United States30 sites
  • University of Buffalo

    Buffalo, New York, 14075

  • Mercy San Juan Medical Center

    Carmichael, California, 95608

  • Medical University of South Carolina

    Charleston, South Carolina, 29425

  • University of Virginia

    Charlottesville, Virginia, 22908

  • Tennessee Interventional and Imaging Associates

    Chattanooga, Tennessee, 37403

  • Rush University

    Chicago, Illinois, 60612

  • University of Illinois

    Chicago, Illinois, 60612

  • Geisinger Clinic

    Danville, Pennsylvania, 17822

  • Duke University Medical Center

    Durham, North Carolina, 27710

  • University of Florida

    Gainesville, Florida, 32608

  • Greenville Health System

    Greenville, South Carolina, 61103

  • Baptist Medical Center

    Jacksonville, Florida, 32207

  • University of Tennessee

    Knoxville, Tennessee, 37920

  • Norton Healthcare

    Louisville, Kentucky, 40241

  • University of Miami

    Miami, Florida, 33136

  • Mount Sinai Hospital

    New York, New York, 10029

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104

  • University of California Irvine

    Orange, California, 92868

  • Texas Stroke Institute

    Plano, Texas, 75075

  • Oregon Health and Science University

    Portland, Oregon, 97239

  • Javon Bea Hospital

    Rockford, Illinois, 61103

  • University of Utah

    Salt Lake City, Utah, 84132

  • Memorial Health University

    Savannah, Georgia, 31405

  • Maine Medical Center

    Scarborough, Maine, 04074

  • St. Louis University

    St Louis, Missouri, 63110

  • Stony Brook University

    Stony Brook, New York, 11794

  • Mercy Health St. Vincent Medical Center

    Toledo, Ohio, 43604

  • University of Arizona

    Tucson, Arizona, 85724

  • Westchester Medical Center

    Valhalla, New York, 10595

  • University of Massachusetts

    Worcester, Massachusetts, 01655

Other trials in United States

Japan6 sites
  • Aichi Medical University Hospital

    Aichi

  • Okayama University Hospital

    Okayama

  • National Hospital Organization Osaka National Hospital

    Osaka

  • Tominaga Hospital

    Osaka

  • Kohnan Hospital

    Sendai

  • Meihokai Yokohama Shin-Toshi Brain Orthopedic Hospital

    Yokohama

Other trials in Japan

France5 sites
  • Centre Hospitalier Universitaire d'Amiens Picardie

    Amiens

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux

  • Hopital Roger Salengro-Centre Hospitalier Universitaire de Lille

    Lille

  • Praticien Hospitalier Université de Lorraine

    Nancy

  • Centre Hospitalier Regional Universitaire de Tours

    Tours

Other trials in France

Italy3 sites
  • Ospedale Niguarda Ca' Granda

    Milan

  • Policlinico Tor Vergata

    Roma

  • Ospedale Cannizzaro

    Sicily

Other trials in Italy

Switzerland2 sites
  • Hopitaux Universitaires de Geneve

    Geneva

  • University Hospital Zurich

    Zurich

Other trials in Switzerland

Belgium1 site
  • Algemeen Ziekenhuis Groeninge

    Kortrijk

Other trials in Belgium

Germany1 site
  • Universitatsklinikum Schleswig Holstein

    Lübeck

Other trials in Germany

Israel1 site
  • Galilee Hospital Naharyia

    Nahariya

Other trials in Israel

Portugal1 site
  • Centro Hospitalar de Vila Nova de Gaia

    Porto

Other trials in Portugal

Spain1 site
  • Hospital Universitari i Politecnic La Fe

    Valencia

Other trials in Spain

About this study

Official title: A Prospective, Multi-center, Single Arm Study to Obtain "Real World" Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils Including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms

A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils

Read the detailed description

A registry to collect real world data on the use of Cerenovus coils. The study will be a post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils

Conditions
Aneurysms
Being tested
MICRUSFRAME and GALAXY coils
Medical subject headings
Aneurysm

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MICRUSFRAME and GALAXY coilsDevice

    MICRUSFRAME and GALAXY Coils

Study groups in NCT03642639
Study groupRoleWhat they receive
CoilsOtherMICRUSFRAME and GALAXY coils
Receives: Device: MICRUSFRAME and GALAXY coils

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Who Achieved Adequate Occlusion (Modified Raymond-Roy I or II Classification) as Assessed by the Independent Core Lab Report of the Target Aneurysm at 1 Year Without Retreatment

    Number of participants who achieved adequate occlusion as assessed by the independent core lab report of the target aneurysm at 1 year without retreatment was reported. Adequate occlusion was defined as the achievement of a Modified Raymond-Roy classification of the aneurysm at 1 year without retreatment. Modified Raymond-Roy Classification scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.

    Measured: At 1 year Post Procedure on Day 1

Secondary outcomes (6)
  1. Packing Density Percentage (%) as Assessed by Independent Core Lab

    Packing density was defined as the ratio of the volume of coils to the volume of the coiled part of the aneurysm achieved during the procedure. Packing density is expressed as percentage.

    Measured: During procedure (Day 1)

  2. Number of Participants With Complete Occlusion at 1 Year as Assessed by the Independent Core Lab (Modified Raymond-Roy I Classification)

    Number of participants with complete occlusion at 1 year was reported as assessed by the independent core lab was reported. Complete occlusion was defined as achieving Modified Raymond-Roy I classification at 1 year, as assessed by the independent core lab. Modified Raymond-Roy I or II Classification scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.

    Measured: At 1 year Post Procedure on Day 1

  3. Recanalization Rate at 1 Year as Assessed by Independent Core Lab

    Recanalization rate is defined as number of participants with recanalization. Recanalization was defined as a worsening in aneurysm occlusion grading using the Modified Raymond-Roy Classification (MRRC) scale. MRRC scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.

    Measured: At 1 year Post Procedure on Day 1

  4. Number of Participants With Modified Rankin Score (mRS) 0-2 With Unruptured Aneurysms

    Number of participants with mRS 0-2 with unruptured aneurysm was reported. The Modified Rankin Scale (mRS) is a 7 point measure of functional outcome ranging from 0 to 6, where higher scores indicate greater disability. A score of 0 reflects no symptoms, 1 denotes no significant disability despite minor symptoms, 2 indicates slight disability with independence in personal affairs, 3 corresponds to moderate disability requiring some help but able to walk unassisted, 4 represents moderately severe disability with dependence for bodily needs and inability to walk alone, 5 signifies severe disability requiring constant care, and 6 indicates death. Increasing scores indicate worsening outcomes.

    Measured: From baseline (Day 1 of procedure) to 1 year post procedure on Day 1

  5. Number of Participants With Retreatment (Surgical or Endovascular)

    Number of participants with any retreatment (surgical or endovascular) was reported. Retreatment is defined as any type of additional treatment (surgical or endovascular) of the target aneurysm after the index procedure.

    Measured: From baseline (Day 1 of procedure) to 1 year post procedure on Day 1

  6. Number of Participants With Device Related Serious Adverse Events (SAEs)

    An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, users or other persons, whether or not related to the investigational medical device and whether anticipated or unanticipated. A serious adverse event (SAE) is defined as an adverse event that led to death, led to serious deterioration in the health of the participant, users, other persons as defined by one or more of the following: a life-threatening illness or injury, or a permanent impairment of a body structure or a body function including chronic diseases, or in-patient or prolonged hospitalization, or medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function led to fetal distress, fetal death or a congenital abnormality or birth defect including physical or mental impairment.

    Measured: From Day of procedure (Day 1) up to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2018
  2. Study start23 Aug 2018
  3. Primary completion12 Jun 2025
  4. Study completion12 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
723 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03642639
Sponsor's protocol ID
CNV_2017_01
Acronym
STERLING
Status last verified
Jun 2026
First submitted
11 Jul 2018
Last updated
9 Jul 2026
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A study testing MICRUSFRAME and GALAXY coils in people with Aneurysms, run by Cerenovus, Part of DePuy Synthes Products, Inc. at 51 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 51 sites in United States, Japan, France, Italy, Switzerland and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Who Achieved Adequate Occlusion (Modified Raymond-Roy I or II Classification) as Assessed by the Independent Core Lab Report of the Target Aneurysm at 1 Year Without Retreatment (time frame: At 1 year Post Procedure on Day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in